High SEPT9_v1 expression is associated with poor clinical outcomes in head and neck squamous cell carcinoma

Translational Oncology

Volumn 3, Issue 4, 2010, Pages 239-245

  Stanbery, Laura ^a   D'Silva, Nisha J ^a,b,c   Lee, Julia S ^a,c   Bradford, Carol R ^b,c   Carey, Thomas E ^b,c   Prince, Mark E ^b,c   Wolf, Gregory T ^b,c   Worden, Francis P ^a   Cordell, Kitrina G ^a,b   Petty, Elizabeth M ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ISOPROTEIN; PROTEIN; PROTEIN ANTIBODY; PROTEIN SEPT9; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIUM; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 77955688071     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10109     Document Type: Article

References (24)

1. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, and Riou G (1995). High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10, 1217-1227.
2. Gotte K, Riedel F, Neubauer J, Schafer C, Coy JF, and Hormann K (2001). The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer. Int J Oncol 19, 331-336.
3. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, et al. (2008). EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26, 3128-3137.
4. Nogueira CP, Dolan RW, Gooey J, Byahatti S, Vaughan CW, Fuleihan NS, Grillone G, Baker E, and Domanowski G (1998). Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope 108, 345-350.
5. Yeudall WA, Jakus J, Ensley JF, and Robbins KC (1997). Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol Carcinog 18, 89-96.
6. Okami K, Reed AL, Cairns P, Koch WM, Westra WH, Wehage S, Jen J, and Sidransky D (1999). Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 18, 3541-3545.
7. Rawnsley JD, Srivatsan ES, Chakrabarti R, Billings KR, and Wang MB (1997). Deletion analysis of the p16/CDKN2 gene in head and neck squamous cell carcinoma using quantitative polymerase chain reaction method. Arch Otolaryngol Head Neck Surg 123, 863-867.
8. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, et al. (1996). High frequency of p16 (CDKN2/MTS-1/ INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56, 3630-3633.
9. Yarbrough WG (2002). The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope 112, 2114-2128.
10. Wang X, Pavelic ZP, Li YQ, Wang L, Gleich L, Radack K, Gluckman JL, and Stambrook PJ (1995). Amplification and overexpression of the cyclin D1 gene in head and neck squamous cell carcinoma. Clin Mol Pathol 48, M256-M259.
11. Kalyankrishna S and Grandis JR (2006). Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24, 2666-2672.
12. Pomerantz RG and Grandis JR (2003). The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep 5, 140-146.
13. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, and Elenius K (2006). Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12, 4103-4111.
14. Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D, and Plass C (2008). Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 68, 4494-4499.
15. Amir S, Wang R, Matzkin H, Simons JW, and Mabjeesh NJ (2006). MSF-A interacts with hypoxia-inducible factor-1α and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. Cancer Res 66, 856-866.
16. Burrows JF, Chanduloy S, McIlhatton MA, Nagar H, Yeates K, Donaghy P, Price J, Godwin AK, Johnston PG, and Russell SE (2003). Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol 201, 581-588.
17. Gonzalez ME, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, and Petty EM (2007). High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Res 67, 8554-8564.
18. Douglas LM, Alvarez FJ, McCreary C, and Konopka JB (2005). Septin function in yeast model systems and pathogenic fungi. Eukaryot Cell 4, 1503-1512.
19. Hall PA and Russell SE (2004). The pathobiology of the septin gene family. J Pathol 204, 489-505.
20. Gonzalez ME, Makarova O, Peterson EA, Privette LM, and Petty EM (2009). Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells. Cell Signal 21, 477-487.
21. Gross ND, Boyle JO, Du B, Kekatpure VD, Lantowski A, Thaler HT, Weksler BB, Subbaramaiah K, and Dannenberg AJ (2007). Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma. Clin Cancer Res 13, 5910-5917.
22. Scott M, McCluggage WG, Hillan KJ, Hall PA, and Russell SE (2006). Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer 118, 1325-1329.
23. Bennett KL, Lee W, Lamarre E, Zhang X, Seth R, Scharpf J, Hunt J, and Eng C (2004). HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas. Genes Chromosomes Cancer 49, 319-326.
24. Nagata K, Asano T, Nozawa Y, and Inagaki M (2004). Biochemical and cell biological analyses of a mammalian septin complex, Sept7/9b/11. J Biol Chem 279, 55895-55904.